The Transactions Haven’t Changed. The Network Has. Flying home from the HDA Traceability Seminar last week, I saw some news from Philadelphia that put much of what we had spent the previous few days discussing […]

What comes next for DSCSA OPERATIONS AND INTEROPERABILITY Thirteen years after DSCSA became law, the industry’s focus is shifting from implementation to sustained operation. At the 2026 HDA Traceability Seminar, discussions increasingly centered on what […]

Within this slide deck, you can explore how GLP-1 demand, telehealth, digital pharmacies, and direct-to-consumer distribution are reshaping the pharmaceutical supply chain and creating new patient safety and security challenges. Rx-360’s Ryan Kelly, Interim CEO […]

Ensuring patient safety depends on the integrity of global pharmaceutical supply chains—yet Supplier Quality professionals continue to face practical, structural challenges in how audits are conducted, documented, and leveraged for assurance.   To better understand current practices, Rx‑360 […]

Optimize Supplier Corrective Actions with Rx‑360’s SCAR Template The Supplier Quality Working Group at Rx‑360 has developed a standardized Supplier Corrective Action Report (SCAR) template designed to strengthen pharmaceutical supply chain integrity and improve quality […]

Rx-360 is committed to supporting the global pharmaceutical industry in meeting regulatory standards worldwide. In response to the National Medical Products Administration (NMPA) release of Appendices One and Two of Article 310 of the Good […]

The BIOSECURE Act did not arrive with ceremony. It arrived embedded in the National Defense Authorization Act, debated largely in abstractions, and passed with little public attention. But for pharmaceutical and biotechnology companies operating global […]